Note a recent summary of deficiencies observed by PQT Medicines when reviewing bioequivalence study protocols from manufacturers
M
First dihydroartemisinin/piperaquine 30mg/240mg dispersible tablet prequalified
M
WHO Prequalification Unit (PQT) added the below new product to its prequalified list:
First pretomanid prequalified
M
WHO Prequalification Unit (PQT) added the below new product to its prequalified list:
Remdesivir removed from the PQT Invitations for Expression of Interest (EOIs) (FPPs and APIs)
M
Remdesivir removed from the PQT Invitations for Expression of Interest (EOIs) (FPPs and APIs).
See link for recent World Health Organization (WHO) recommendations:
New Invitation for Expression of Interest (EOI) for Active Pharmaceutical Ingredients (APIs) published
M
New Invitation for Expression of Interest (EOI) for Active Pharmaceutical Ingredients (APIs) published
New Invitation for Expression of Interest (EOI) to manufacturers of antimalarial medicines published
M
New Invitation for Expression of Interest (EOI) to manufacturers of antimalarial medicines published